Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSmith & Nephew Regulatory News (SN.)

Share Price Information for Smith & Nephew (SN.)

Share Price is delayed by 15 minutes
Get Live Data
1,139.00    -8.00 (-0.70%)
Bid:
1,141.00
Ask:
1,141.50
Spread: 0.50 (0.044%)
Market Cap: £9.66b
SN. Live PriceLast checked at - London Stock Exchange

Intraday Smith & Nephew Share Chart

Transaction in Own Shares

1 Mar 2022 18:12

RNS Number : 2846D
Smith & Nephew Plc
01 March 2022
 

1 March 2022

Smith & Nephew plc

Transaction in Own Shares

Smith & Nephew plc (the "Company") announces today it has purchased the following number of its own ordinary shares of US 20¢ each through Merrill Lynch International, as part of its USD $125 million share buyback programme announced on 22 February 2022 and in accordance with the authority granted by shareholders at the Company's Annual General Meeting on 14 April 2021.

 

Aggregated details of share purchase transactions according to trading venue are set out below:

 

Date of transaction:

Venue:

Number of ordinary shares repurchased:

Highest price paid per ordinary share (GBP):

Lowest price paid per ordinary share (GBP):

Volume weighted average price paid per ordinary share (GBP):

01/03/2022

XLON

51,148

£13.3250

£13.0250

£13.1597

01/03/2022

BATE

0

£0.00

£0.00

£0.00

01/03/2022

CHIX

0

£0.00

£0.00

£0.00

 

The Company intends to hold these shares in Treasury and then cancel them.

Since 23 February 2022, the Company has purchased 383,588 shares at a cost (including dealing and associated costs) of £4,954,046.18.

 

Following the purchase of these shares, the Company holds 5,703,323 of its shares in Treasury. The Company's issued share capital, with one voting right per share consists of 879,501,695 ordinary shares of US20¢ each (excluding treasury shares). This figure of 879,501,695 is the figure which should be used by shareholders as the denominator when determining whether they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

These purchases were made by Merrill Lynch International on behalf of the Company.

This announcement is made in accordance with the requirements of LR 12.4.6.

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018), a full breakdown of the individual purchases is attached to this announcement.

http://www.rns-pdf.londonstockexchange.com/rns/2846D_1-2022-3-1.pdf

 

 

Sarah Carne

Deputy Company Secretary

Smith & Nephew plc

 

Tel: 01923 477100

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
POSSSAFAFEESESD
Date   Source Headline
5th Jun 202612:12 pmRNSTransaction in Own Shares
4th Jun 20264:05 pmRNSDirector/PDMR Shareholding
3rd Jun 202611:21 amRNSDirector/PDMR Shareholding
3rd Jun 202610:35 amRNSAdmission to Trading
1st Jun 20263:10 pmRNSTotal Voting Rights
29th May 202610:37 amRNSTransaction in Own Shares
27th May 20269:31 amRNSPre Stabilisation Notice
22nd May 20261:32 pmRNSAdmission to Trading
22nd May 20269:58 amRNSTransaction in Own Shares
20th May 202611:25 amRNSDirector/PDMR Shareholding
19th May 20268:53 amRNSHolding(s) in Company
15th May 202612:28 pmRNSTransaction in Own Shares Replacement
15th May 202611:41 amRNSTransaction in Own Shares
14th May 20269:25 amRNSHolding(s) in Company
12th May 20264:03 pmRNSSterling Amount of Dividend
8th May 20267:00 amRNSShare Buyback Programme
6th May 20262:25 pmRNSResult of AGM
6th May 20267:00 amRNSSmith+Nephew First Quarter 2026 Trading Update
1st May 20261:10 pmRNSTotal Voting Rights
27th Apr 20267:00 amRNSExpert surgeons insights event for investors
22nd Apr 20268:46 amRNSNotice of Results
16th Apr 202611:12 amRNSDirector/PDMR Shareholding
15th Apr 20263:46 pmRNSDirector Declaration
14th Apr 20262:59 pmRNSReplacement: Annual Financial Report & AGM Notice
1st Apr 202612:23 pmRNSTotal Voting Rights
24th Mar 20264:16 pmRNSDirector/PDMR Shareholding
24th Mar 20268:45 amRNSHolding(s) in Company
16th Mar 20263:08 pmRNSAnnual Financial Report & Notice of AGM
16th Mar 20263:08 pmRNSAnnual Financial Report & Notice of AGM
10th Mar 20262:30 pmRNS-RSmith+Nephew launches next-generation ALLEVYN™ COMPLETE CARE Foam Dressing - designed for high performance in wound management and pressure injury prevention
5th Mar 20267:30 amRNSDirector Declaration
2nd Mar 20261:36 pmRNSTotal Voting Rights
2nd Mar 20267:00 amRNSFinal Results
5th Feb 202611:56 amRNSNotice of Results
2nd Feb 20264:00 pmRNSBLOCK LISTING SIX MONTHLY RETURN
2nd Feb 20263:05 pmRNSTotal Voting Rights
23rd Jan 20262:00 pmRNSDirector/PDMR Shareholding
21st Jan 20264:11 pmRNSCompletion of Acquisition
12th Jan 20264:30 pmRNSAcquisition of Integrity Orthopaedics
2nd Jan 202610:07 amRNSTotal Voting Rights
8th Dec 20257:00 amRNSNew Strategy and 2028 Financial Targets
1st Dec 20254:10 pmRNSTotal Voting Rights
19th Nov 202510:00 amRNSDirector/PDMR Shareholding
18th Nov 202510:18 amRNSHolding(s) in Company
12th Nov 20259:24 amRNSDirector/PDMR Shareholding
11th Nov 20254:40 pmRNSHolding(s) in Company
10th Nov 20251:46 pmRNSDirector/PDMR Shareholding
7th Nov 20259:38 amRNSDirector/PDMR Shareholding
7th Nov 20259:35 amRNSDirector/PDMR Shareholding
6th Nov 20257:01 amRNSDirectorate change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.